Contents

Search

Relefact (thyrotropin-releasing hormone, TRH, Thypinone)

Pharmacology: Indications: 1) adjunct agent in the assessment of thyroid function 2) adjunct to other procedures in the assessment of patients with pituitary or hypothalamic disorders 3) used in the assessment of abnormal control of prolactin secretion Dosage: 1) adults: 500 ug (200-500 ug) 2) children: 7 ug/kg to a maximum dose of 500 ug Injection: 500 ug/mL (1 mL) Adverse effects: 1) common (> 10%) - headache, flushing of the face, nausea, dry mouth, lightheadedness, urge to urinate 2) less common (1-10%) - breast enlargement & galactorrhea in lactating women, taste disturbance, abdominal discomfort, anxiety, sweating, tingling 3) uncommon (< 1%) - severe hypotension, temporary loss of vision Mechanism of action: 1) thyrotropin-releasing hormone (TRH) 2) induces release of thyroid-stimulating hormone from the anterior pituitary 3) induces release of prolactin from the pituitary

Related

thyroid-stimulating hormone (TSH) or thyrotropin thyrotropin-releasing hormone receptor; TRH-R; thyroliberin receptor (TRHR) TRH stimulation test

General

thyrotropin-releasing hormone; thyroliberin; protirelin (TRH) endocrine agent

References

  1. Gkonos et al Mol Endocrinol 1989 Dec;3(12):2101-9
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. Department of Veterans Affairs, VA National Formulary